The durability and breadth of our candidate vaccine remain to be determined, but it has been shown previously that nanoparticle-conjugated TLR9 agonists improve the potency, durability, and breadth of COVID-19 vaccines [43]. The gene discussed is TLR9; the disease is COVID-19.